Mycobacterium tuberculosis specific T cell HLA-A*0201 restrictive epitope peptide pMtb 8 and application thereof
The invention discloses a mycobacterium tuberculosis specific T cell HLA-A * 0201 restrictive epitope peptide pMtb 8 and application thereof, and belongs to the field of biotechnology and medicine. According to the invention, a bioinformatics prediction method and an ultraviolet induced peptide replacement experiment are combined, the epitope peptide with antituberculous activity is screened by using the antigen of mycobacterium tuberculosis, and the affinity between the epitope peptide pMtb 8 and the HLA-A * 0201 molecule is efficiently and accurately detected. The HLA-A * 0201 restrictive mycobacterium tuberculosis epitope peptide is a novel and unreported HLA-A * 0201 restrictive mycobacterium tuberculosis epitope peptide, and is recognized by specific CD8 + T cells in a tuberculosis patient and induced to be activated. The HLA-A * 0201 genotype is one of the most widely carried HLA genotypes in people, determination of the epitope peptide provides a theoretical basis and a new solution for research and development of tuberculosis vaccines, diagnostic reagents and therapeutic drugs, and the epitope peptide has practical significance in prevention and treatment of tuberculosis..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 12. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIU SUDONG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-12, Last update posted on www.tib.eu: 2024-04-30, Last updated: 2024-05-03 |
|---|
| Patentnummer: |
CN117384262 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001438182 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001438182 | ||
| 003 | DE-627 | ||
| 005 | 20240503105014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001438182 | ||
| 035 | |a (EPA)CN117384262 | ||
| 035 | |a (EPA)89462455 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIU SUDONG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mycobacterium tuberculosis specific T cell HLA-A*0201 restrictive epitope peptide pMtb 8 and application thereof |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-12, Last update posted on www.tib.eu: 2024-04-30, Last updated: 2024-05-03 | ||
| 520 | |a The invention discloses a mycobacterium tuberculosis specific T cell HLA-A * 0201 restrictive epitope peptide pMtb 8 and application thereof, and belongs to the field of biotechnology and medicine. According to the invention, a bioinformatics prediction method and an ultraviolet induced peptide replacement experiment are combined, the epitope peptide with antituberculous activity is screened by using the antigen of mycobacterium tuberculosis, and the affinity between the epitope peptide pMtb 8 and the HLA-A * 0201 molecule is efficiently and accurately detected. The HLA-A * 0201 restrictive mycobacterium tuberculosis epitope peptide is a novel and unreported HLA-A * 0201 restrictive mycobacterium tuberculosis epitope peptide, and is recognized by specific CD8 + T cells in a tuberculosis patient and induced to be activated. The HLA-A * 0201 genotype is one of the most widely carried HLA genotypes in people, determination of the epitope peptide provides a theoretical basis and a new solution for research and development of tuberculosis vaccines, diagnostic reagents and therapeutic drugs, and the epitope peptide has practical significance in prevention and treatment of tuberculosis. | ||
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a GU XIAODONG |e verfasserin |4 aut | |
| 700 | 0 | |a WENG RUIQIANG |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 12. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89462455/publication/CN117384262A1?q=CN117384262 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 01 | ||